Article in Molecular cancer research : MCR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Renyta MosesDepartment of Medicine, Division of Hematology-Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.ORCID 0000-0003-4708-2958
Alexandra IndegliaGraduate Group in Biochemistry and Molecular Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.ORCID 0000-0001-9035-4969
Alison S LevineDana-Farber Cancer Institute , Harvard Medical School, Boston, Massachusetts.ORCID 0000-0003-3861-4203
Ryan HauslerDepartment of Medicine, Division of Hematology-Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.ORCID 0009-0005-4965-0017
Gregory KellyDepartment of Medicine, Division of Hematology-Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.ORCID 0009-0002-0474-2856
Sven A MillerCancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.ORCID 0000-0001-7295-5592
Isabel AnezDana-Farber Cancer Institute , Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-0762-6837
Melissa HellerDepartment of Medicine, Division of Hematology-Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.ORCID 0009-0007-4703-5314
Rosella DelgadoDepartment of Medicine, Division of Hematology-Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.ORCID 0009-0003-6003-6232
Caitlin OrrDepartment of Medicine, Division of Hematology-Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.ORCID 0009-0007-4447-2869
Wendy KohlmannHuntsman Cancer Institute , University of Utah, Primary Children's Hospital, Salt Lake City, Utah.ORCID 0000-0002-9134-9640
Anne NaumerHuntsman Cancer Institute , University of Utah, Primary Children's Hospital, Salt Lake City, Utah.ORCID 0009-0001-2956-1720
Jennie VagherHuntsman Cancer Institute , University of Utah, Primary Children's Hospital, Salt Lake City, Utah.ORCID 0009-0004-5818-6589
Sophie R CahillDana-Farber Cancer Institute , Harvard Medical School, Boston, Massachusetts.ORCID 0000-0001-7456-0113
Luke D MaeseHuntsman Cancer Institute , University of Utah, Primary Children's Hospital, Salt Lake City, Utah.ORCID 0000-0002-8739-9100
John KaranicolasCancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.ORCID 0000-0003-0300-726X
Judy E GarberDana-Farber Cancer Institute , Harvard Medical School, Boston, Massachusetts.ORCID 0000-0001-9449-3982
Maureen E MurphyProgram in Molecular and Cellular Oncogenesis, Wistar Institute, Philadelphia, Pennsylvania.ORCID 0000-0001-7644-7296
Kara N MaxwellDepartment of Medicine, Division of Hematology-Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.ORCID 0000-0001-8192-4202
Funding
UTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Jared P Rutter · 1986 to 2026
$72.6M
Precision approaches to refining TP53-associated cancer riskR01CA242218 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI AMOS, CHRISTOPHER I., GARBER, JUDY E. · 2019 to 2023
$8.5M
Refolding Mutant p53: A Strategy for Cancer Prevention in Li-Fraumeni SyndromeU54CA272686 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI Edna Cukierman · 2022 to 2026
$8.3M
Functional Analysis of p53 Polymorphic Variants - Diversity SupplementR01CA102184 · NCI · WISTAR INSTITUTE · PI Maureen E. Murphy · 2005 to 2026
$7.4M
The genetics of tumor suppression by p53 - Diversity SupplementR01CA279585 · NCI · WISTAR INSTITUTE · PI Maureen E. Murphy · 2023 to 2026
$1.7M
A genotype-phenotype study of tumors from patients with inherited mutations in DNA repair genesK08CA215312 · NCI · UNIVERSITY OF PENNSYLVANIA · PI MAXWELL, KARA N · 2018 to 2022
$924k
Role of PADI4 as a key epigenetic regulator of the p53 pathway and tumor suppressionF31CA277953 · NCI · UNIVERSITY OF PENNSYLVANIA · PI INDEGLIA, ALEXANDRA · 2023 to 2024
$55k
Burroughs Wellcome Fund (BWF) 1017184Li Fraumeni Syndrome AssociationNational Cancer Institute (NCI) F31CA277953National Cancer Institute (NCI) K08CA215312National Cancer Institute (NCI) P30CA042014National Cancer Institute (NCI) R01CA102184National Cancer Institute (NCI) R01CA242218National Cancer Institute (NCI) U54CA272686NCI NIH HHS F31 CA277953NCI NIH HHS K08 CA215312NCI NIH HHS P30 CA042014NCI NIH HHS R01 CA102184NCI NIH HHS R01 CA242218NCI NIH HHS R01 CA279585NCI NIH HHS U54 CA272686
6 · The paper itself
Abstract
The p53 tumor suppressor binds DNA cooperatively as a tetramer, mediated by salt-bridge interactions between p53 residues E180 and R181 from 2 different p53 monomers. Variants at the R181 residue are one of the most identified TP53 pathogenic variants by germline genetic testing. We show that families with TP53 p.R181H and p.R181C variants have an attenuated cancer risk phenotype compared with patients with hotspot dominant-negative loss-of-function TP53 variants. Despite this phenotype, we find that p53 R181H and R181C variants have significantly reduced ability to bind to p53 promoter/enhancer target sequences and transactivate p53 target genes, similar to null variants. However, p53 R181H and R181C retain wild-type (WT) p53 structure and tetramerization. In addition, R181-mutant cells undergo apoptosis through WT p53 activity at the mitochondria. These results suggest that retention of transcription-independent p53 tumor suppressor function results in a reduced penetrance cancer risk syndrome in humans. IMPLICATIONS: We report the first separation of function DNA-binding domain p53 mutation that results in retention of transcription-independent p53 functions despite loss of p53 transactivation activity, resulting in a reduced penetrance phenotype.
Indexed as
DNAMitochondriaTumor Suppressor Protein p53ApoptosisHumansProtein BindingDNATP53 protein, humanTumor Suppressor Protein p53
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Variation at the R181 Residue of p53 Confers Loss of p53 DNA Binding Cooperativity with the Retention of Mitochondria-Associated Apoptosis. · full record | OpenQuestion